The heat on healthcare’s middlemen — pharmacy benefit managers (PBM) — is increasing, but a tangible solution may still be far off. Lawmakers grilled PBM executives Tuesday at the third hearing in a ...
The conclusion of the longest government shutdown in history and rising political acrimony rightly receives a great deal of attention but this focus makes it easy to overlook areas where beneficial ...
Bipartisan policies in Congress meant to lower drug costs by targeting middlemen in the pharmaceutical supply chain are likely to run up against a fundamental issue: the three major pharmacy benefit ...
Shortly after releasing a scathing interim report in July that revealed how three players dominate the pharmacy benefit manager market and raise drug costs for patients, the Federal Trade Commission ...
In a conversation hosted by DSN, EmpiRx Health CEO Danny Sanchez and EmpiRx Health President John Ridyard detailed how their mid-market PBM is gaining traction by putting pharmacists at the center of ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The ...
The House Committee on Oversight and Government Reform said last week that it’s expanding its investigation into the role of pharmacy benefit managers by seeking information about how they use foreign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results